Science 37 Increases Global Presence for Its Decentralized Trials Platform
Science 37, which offers a virtual trials platform to connect participants to researchers via telehealth and a network of home-health nurses, is expanding its global reach by adding staff to its nurse and investigator networks in Europe, Latin America, Asia and a center in Slovakia.
Drugmakers are backing Science 37’s trial platform. On Friday, Science 37 closed a $40 million funding deal for its technology platform, snagging investments from Amgen, Sanofi Ventures and Novartis. Other contributors who are backing the company’s technology include PPD, Redmile Group, Lux Capital, LifeSci Ventures and Mubadala Ventures.
Science 37’s virtual trials platform is available in more than 40 languages and is set to be deployed in more than 30 countries.